WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the results of its collaboration with the Karolinska Institute on a groundbreaking clinical study, called Stockholm 3 (STHLM3), aimed at developing a more effective test for prostate cancer than using the prostate-specific antigen (PSA) alone. With an estimated 307,000 deaths worldwide in 2012, prostate cancer remains the fifth leading cause of death from cancer in men.1
Help employers find you! Check out all the jobs and post your resume.
